## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($337.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Stryker Corp. stock: steady climb, cautious optimism as Wall Street eyes medtech resilience**
- Source: AD HOC NEWS | 20260101T041715 | Bullish | Relevance: 100%
- Stryker Corp.'s stock has shown a steady upward trend, outperforming its medtech peers and nearing record highs, driven by strong fundamentals and growth in surgical robotics and orthopedics. Despite cautious sentiment from some analysts regarding valuation, the overall Wall Street verdict is constructive, positioning Stryker as a core holding with further upside potential. Long-term investors who have held the stock have been rewarded with double-digit percentage gains over the past year.

**2. Stryker Corp. stock: steady climb, cautious optimism as Wall Street eyes medtech resilience**
- Source: AD HOC NEWS | 20260101T040837 | Bullish | Relevance: 100%
- Stryker Corp. has shown a pattern of steady stock price growth, outperforming its medtech peers with quiet confidence due to patient buying and a focus on high-quality healthcare growth. Analysts maintain a constructive stance, seeing it as a high-quality play on structural growth in orthopedic and surgical procedures despite some valuation concerns. The company's future prospects are driven by demographics, technological differentiation in surgical robotics, and disciplined capital allocation.

**3. Ascent Group LLC Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251231T084735 | Bullish | Relevance: 100%
- Ascent Group LLC significantly increased its stake in Stryker Corporation by 124.4% in Q3, now owning 13,038 shares valued at approximately $4.82 million. This comes as Stryker reported strong quarterly earnings, exceeding EPS expectations and increasing its dividend, despite recent large insider selling activity. Institutional investors currently hold about 77.09% of the medical technology company's stock, while analysts maintain a "Moderate Buy" consensus rating.

**4. Surgical Robotics Market to Reach US$ 15.25 Billion by 2033**
- Source: openPR.com | 20260102T072601 | Bullish | Relevance: 86%
- The global surgical robotics market is projected to grow from US$ 5.84 billion in 2024 to US$ 15.25 billion by 2033, driven by increasing preference for minimally invasive surgeries, technological advancements, and the rising burden of chronic diseases. North America currently leads the market with a 42% share, while the Asia Pacific region is expected to show high growth. Key players include Intuitive Surgical, Stryker Corporation, and CMR Surgical.

**5. ISRG Sees 91% SP Growth: A Turning Point for Single-Port Surgery?**
- Source: The Globe and Mail | 20251231T140833 | Somewhat-Bullish | Relevance: 70%
- Intuitive Surgical's single-port (SP) platform saw a 91% year-over-year growth in procedures during Q3 2025, driven by strong adoption in Korea and expanding indications in the U.S. This surge, coupled with regulatory advancements and positive clinical evidence, suggests SP surgery is transitioning from a niche to a more mainstream application, potentially serving as an incremental growth driver for the company. While the U.S. market is still in early stages, regulatory submissions and initial domestic use in new procedures like colorectal and thoracic surgeries are broadening its addressable market.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Citizens | $440 | $0 | 0% |
| 2025-12-18 | Truist Securiti | $392 | $400 | -2% |
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Citizens | up | Market Outperform |
| 2025-12-18 | Truist Securiti | main | Hold |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.76M) |
| Sells | 7 ($21.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $21M sold (7 transactions in 90 days).
2. Long-term trend broken: trading 7.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 23.3x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($21.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $133.2B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 23.3 |
| Current P/E | 25.7 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). Below SMA200 (0.93x), long-term trend not supportive. OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.66% (CS: 27) | Neutral |
| RSI_14 | 36.2 | Neutral |
| MACD Histogram | -0.09 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.961x | Below |
| vs SMA200 | 0.929x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $348.18
- **Stop Loss:** $337.36 (3.1% risk)
- **Target:** $359.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 133
- **Position Value:** $46,307.94
- **Portfolio %:** 46.31%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*